The discovery of a new antibiotic has brought fresh hope that a looming health crisis caused by drug resistant infections can be avoided. Called teixobactin, it is the result of a private public collaboration involving universities in the US and Germany, and the US biotech company NovoBiotic pharmaceuticals. Andrew Ward, pharmaceuticals correspondent, talks to Clive Cookson, science editor, about the discovery.

iTunes Stitcher audioBoom SoundCloud Overcast RSS


Copyright The Financial Times Limited 2017. All rights reserved.
myFT

Follow the topics related to this show

Comments have not been enabled for this podcast.